Detalhe da pesquisa
1.
First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B.
Mol Ther
; 30(12): 3587-3600, 2022 12 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36299240
2.
Improvement of Local Cell Delivery Using Helix Transendocardial Delivery Catheter in a Porcine Heart.
Int Heart J
; 58(3): 435-440, 2017 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-28539564
3.
An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.
Circ Res
; 112(5): 816-25, 2013 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23429605
4.
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
JAMA
; 311(1): 62-73, 2014 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24247587
5.
Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model.
Catheter Cardiovasc Interv
; 81(6): 970-7, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22581763
6.
Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.
Circ Res
; 108(7): 792-6, 2011 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-21415390
7.
Comparison of allogeneic vs autologous bone marrowderived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
JAMA
; 308(22): 2369-79, 2012 Dec 12.
Artigo
Inglês
| MEDLINE | ID: mdl-23117550
8.
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.
Am Heart J
; 161(3): 487-93, 2011 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-21392602
9.
Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils: implication of A2a receptor and cAMP/PKA/Ca2+ pathway.
Circ Res
; 99(6): 590-7, 2006 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16917093
10.
Cell therapy for severe chronic heart failure: the Luxembourg experience.
Biomed Mater Eng
; 18(1 Suppl): S27-31, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-18334721
11.
Improvement of exercise-induced cardiac deformation after cell therapy for severe chronic ischemic heart failure.
J Card Fail
; 12(2): 108-13, 2006 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-16520257
12.
Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction.
J Card Fail
; 12(1): 66-72, 2006 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-16500583
13.
Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study).
EuroIntervention
; 7(7): 805-12, 2011 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22082576
14.
Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation.
Anal Biochem
; 338(2): 294-8, 2005 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15745750